$CGEN News
Last published 3d ago
- 3d agoCGENCompugen to Present UnigenX™ Platform at the 18th Annual PEGS Europe SummitPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery...
- 4d agoCGENCompugen Reports Third Quarter 2026 ResultsPR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery...
- 2w agoCGENCompugen to Release Third Quarter 2026 Results on Monday, November 9, 2026PR NewswireHOLON, Israel, Oct. 26, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today announced
- 1mo agoCGENCompugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development ConferencePR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 1mo agoCGENCompugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 2mo agoCGENCompugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment ConferencePR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 3mo agoCGENCompugen Reports Second Quarter 2026 ResultsPR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered ...
- 3mo agoCGENCompugen to Participate in BTIG Biotechnology Conference 2026PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 3mo agoCGENCompugen to Release Second Quarter 2026 Results on Monday, August 3, 2026PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered ...
- 4mo agoCGENCompugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers CongressPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered...
- 5mo agoCGENCompugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
- 5mo agoCGENCompugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug DevelopmentPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 5mo agoCGEN2026 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM - COMPUGEN LTDEarnings Call TranscriptsAll right. Good morning, everyone. I'm Stephen Lilley, one of the senior biotech analysts here at Stifel, and glad to have with us as part of the next session, the CEO of Compugen, Aran Afir. Aran, thanks for joining us
- 5mo agoCGENCompugen Reports First Quarter 2026 ResultsPR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 6mo agoCGENCompugen to Participate in 2026 Stifel Virtual Targeted Oncology ForumPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 6mo agoCGENCompugen to Release First Quarter 2026 Results on Monday, May 18, 2026PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered ...
- 7mo agoCGEN25th Annual Needham Virtual Healthcare ConferenceCOMPUGEN LTDEarnings Call TranscriptsGood morning, everyone, and thank you for joining us at the first day of the Needham & Company Healthcare Conference. It is my pleasure to have with me this morning Eran Ofir, the CEO of CompuGen. Eran, please go ahead a
- 7mo agoCGENCompugen to Participate in 25th Annual Needham Virtual Healthcare ConferencePR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 8mo agoCGENCompugen Reports Fourth Quarter and Full Year 2025 ResultsPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by...
- 8mo agoCGENCompugen to Participate in Upcoming Investor ConferencesPR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered...
- 8mo agoCGENCompugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered ...
- 9mo agoCGENCompugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of DirectorsPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered ...
- 11mo agoCGENCompugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 MillionPR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...
- 1y agoCGENCompugen Reports Third Quarter 2025 ResultsPR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...
- 1y agoCGENCompugen to Participate in Stifel 2025 Healthcare ConferencePR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
- 1y agoCGENCompugen to Release Third Quarter 2025 Results on Monday, November 10, 2025PR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
- 1y agoCGENCompugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...
- 1y agoCGENCompugen to Present at SITC 2025PR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery,...
- 1y agoCGENCompugen to Present Research at the Single Cell Genomics 2025 ConferencePR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery,...
- 1y agoCGENCompugen to Present at the H.C. Wainwright 27th Annual Global Investment ConferencePR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...
- 1y agoCGENCompugen Ltd. (CGEN) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCGENCompugen Reports Second Quarter 2025 ResultsPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...
- 1y agoCGENCompugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resistant Ovarian Cancer at ESMO 2025PR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
- 1y agoCGENCompugen to Release Second Quarter 2025 Results on Wednesday, August 6, 2025PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target...
- 1y agoCGENCompugen Announces First Patient Dosed in COM701 Global Platform Trial in Platinum Sensitive Ovarian CancerPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery...
- 1y agoCGENCompugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific ConferencesPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen Reports First Quarter 2025 ResultsPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen Announces Leadership Transitions Effective September 2025PR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen to Release First Quarter 2025 Results on Monday, May 19, 2025PR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen to Participate in Multiple Virtual Investor Conferences in April 2025PR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen Reports Fourth Quarter and Full Year 2024 ResultsPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen to Participate in a Fireside Chat at the 2025 Leerink Partners Global Healthcare ConferencePR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing TechnologyPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoALLTBLRXCGENCGNT+2Cognyte Elects Two New Board Members to Strengthen Expertise and Drive GrowthBusiness WireAnnouncement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global
- 1y agoCGENCompugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025PR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferencePR NewswireCompugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 1y agoCGENCompugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...
- 2y agoCGENCompugen Ltd. (CGEN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoCGENCompugen Reports Third Quarter 2024 ResultsPR NewswireCompugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...